Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

, NVS

Novartis

$80.08

0.22 (0.28%)

16:33
05/18/17
05/18
16:33
05/18/17
16:33

Diplomat Pharmacy now dispensing Novartis' Rydapt for acute myeolid leukemia

Diplomat Pharmacy (DPLO) is now dispensing Rydapt, recently approved by the FDA. Rydapt is manufactured by Novartis (NVS) and is approved to treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The FDA also approved Rydapt to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

NVS

Novartis

$80.08

0.22 (0.28%)

  • 19

    May

  • 06

    Jun

  • 26

    Jun

DPLO Diplomat Pharmacy
$17.44

-0.17 (-0.97%)

03/01/17
BARD
03/01/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy results should satisfy lowered expectations, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy reported Q4 results that were in-line with expectations and provided guidance that is likely ahead of lowered expectations. Coldwell maintained his Outperform rating and $20 price target on Diplomat shares.
03/06/17
BARD
03/06/17
NO CHANGE
Target $20
BARD
Outperform
Significant opportunities ahead for Diplomat Pharmacy, says Baird
Baird analyst Eric Coldwell traveled with Diplomat Pharmacy and now believes there are significant opportunities ahead as its platform remains differentiated and last year reset expectations. Coldwell said crisper execution is required, but he sees a pathway to returning growth in 2018 and beyond. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
05/09/17
LEHM
05/09/17
NO CHANGE
Target $20
LEHM
Overweight
Diplomat Pharmacy price target raised to $20 from $17 at Barclays
Barclays analyst Eric Percher raised his price target for Diplomat Pharmacy to $20 citing the "solid" Q1 results and acquisition of WRB Communications. The analyst maintains an Overweight rating on the shares.
05/09/17
BARD
05/09/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy shares should react positively to 'clean' quarter, says Baird
Baird analyst Eric Coldwell said Diplomat Pharmacy reported its "cleanest and calmest" quarter in a long time and as a result he believes the shares should react positively. He noted the earnings beat, unchanged guidance, and management's enthusiastic comments about upcoming catalysts, including upcoming FDA approvals. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
NVS Novartis
$80.08

0.22 (0.28%)

04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.

TODAY'S FREE FLY STORIES

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees FY17 adjusted EPS $3.53, consensus $3.51 »

Sees FY17 sales $4.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees Q4 adjusted EPS approx. 93c, consensus 93c »

Sees Q4 revenue approx.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFS

Domtar

$44.14

-0.23 (-0.52%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Initiation
Domtar initiated  »

Domtar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ADDYY

adidas

$109.85

-0.45 (-0.41%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Initiation
adidas initiated  »

adidas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$56.05

0.2 (0.36%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Earnings
Asbury Automotive reports Q3 EPS $1.48 with items, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Earnings
Pentair reports Q3 adjusted EPS 95c, consensus 93c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:10
10/24/17
10/24
07:10
10/24/17
07:10
Hot Stocks
Pentair announces new electrical company nVent »

Pentair plc unveiled the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPG

Interpublic Group

$20.63

-0.25 (-1.20%)

07:09
10/24/17
10/24
07:09
10/24/17
07:09
Earnings
Interpublic Group reports Q3 adj. EPS 31c, consensus 33c »

Reports Q3 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AMZN

Amazon.com

$966.30

-16.61 (-1.69%)

07:09
10/24/17
10/24
07:09
10/24/17
07:09
Recommendations
Amazon.com analyst commentary  »

Amazon.com Q3 likely to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 18

    Mar

AGR

Avangrid

$48.27

-0.03 (-0.06%)

07:09
10/24/17
10/24
07:09
10/24/17
07:09
Earnings
Breaking Earnings news story on Avangrid »

Avangrid reports Q3 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 05

    Nov

SMTS

Sierra Metals

$2.46

-0.01 (-0.40%)

07:09
10/24/17
10/24
07:09
10/24/17
07:09
Hot Stocks
Sierra Metals updates on program at Bolivar and Cusi Mines »

Sierra Metals provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$69.95

3.57 (5.38%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Recommendations
VF Corp. analyst commentary  »

VF Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.51

-1.59 (-1.65%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Hot Stocks
AbbVie, Alector announce global strategic collaboration »

AbbVie and Alector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

BHGE

Baker Hughes

$31.47

-1.79 (-5.38%)

, WFT

Weatherford

$3.40

-0.14 (-3.95%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Recommendations
Baker Hughes, Weatherford, Schlumberger, Halliburton analyst commentary  »

Selloff in oil services…

BHGE

Baker Hughes

$31.47

-1.79 (-5.38%)

WFT

Weatherford

$3.40

-0.14 (-3.95%)

SLB

Schlumberger

$61.91

-1.24 (-1.96%)

HAL

Halliburton

$42.24

-1.09 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

BEAT

BioTelemetry

$30.60

-0.55 (-1.77%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Initiation
BioTelemetry initiated  »

BioTelemetry initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYGN

Myriad Genetics

$34.82

-0.04 (-0.11%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Hot Stocks
Myriad Genetics submits BRACAnalysis CDx application for approval in Japan »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

GPK

Graphic Packaging

$14.27

-0.01 (-0.07%)

, IP

International Paper

$58.25

0.04 (0.07%)

07:08
10/24/17
10/24
07:08
10/24/17
07:08
Hot Stocks
Graphic Packaging forms partnership with IP's consumer packaging unit »

Graphic Packaging (GPK)…

GPK

Graphic Packaging

$14.27

-0.01 (-0.07%)

IP

International Paper

$58.25

0.04 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:07
10/24/17
10/24
07:07
10/24/17
07:07
Earnings
Sherwin-Williams sees FY17 EPS $11.20-$11.50 with items, consensus $14.73 »

The company added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ABTX

Allegiance Bancshares

$38.65

-0.35 (-0.90%)

07:07
10/24/17
10/24
07:07
10/24/17
07:07
Earnings
Allegiance Bancshares reports Q4 EPS 22c, consensus 48c »

Reports Q4 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 28

    Nov

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:06
10/24/17
10/24
07:06
10/24/17
07:06
Hot Stocks
Peoples Bancorp, ASB Financial announce definitive merger agreement »

Peoples Bancorp and ASB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AVGO

Broadcom

$244.27

0.03 (0.01%)

07:06
10/24/17
10/24
07:06
10/24/17
07:06
Hot Stocks
Plume, Broadcom announce development and distribution collaboration »

At the Broadband World…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$2.80

-0.2 (-6.67%)

07:06
10/24/17
10/24
07:06
10/24/17
07:06
Hot Stocks
Viking Therapeutics reports 'positive' results from in vivo study of VK2809 »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$88.65

1.21 (1.38%)

07:05
10/24/17
10/24
07:05
10/24/17
07:05
Hot Stocks
Wal-Mart's Sam's Club announces One Day Only Savings Event »

Sam's Club is making…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

SSB

South State

$90.70

-1.45 (-1.57%)

07:04
10/24/17
10/24
07:04
10/24/17
07:04
Earnings
Breaking Earnings news story on South State »

South State reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

GPK

Graphic Packaging

$14.27

-0.01 (-0.07%)

07:04
10/24/17
10/24
07:04
10/24/17
07:04
Earnings
Graphic Packaging reports Q3 adjusted EPS 18c, consensus 18c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.